King gets US, Canadian rights to Avinza from Ligand
Small-molecule developer Ligand has licensed King Pharmaceuticals (markets drugs for hospital/acute care markets and cardiovascular, metabolic, and neurological diseases) US and Canadian rights to the chronic pain drug Avinza (morphine sulfate). King signed a contract sales agreement to promote the product during the transition period until the deal closes.
- Specialty Pharmaceuticals
- Controlled Release
- Includes Contract
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.